ESMO 2026 presidential 2 | HARMONi-GI1: Ivonescimab beats durvalumab in advanced biliary tract cancer! Phase III trial (n=682): Ivonescimab (PD-1/VEGF bispecific antibody) + gemcitabine/cisplatin vs durvalumab + gemcitabine/cisplatin in 1L advanced BTC. 📊 Key results: ✅ Median OS: 14.9 vs 12.1 months (HR 0.75; p=0.0031) ✅ Median PFS: 8.4 vs 5.8 months (HR 0.61; p<0.0001) ✅ ORR: 53.8% vs 32.5% (p<0.0001) ✅ Manageable safety profile; no new safety signals. 🔥 25% reduction in risk of death and 39% reduction in risk of progression! A rare head-to-head phase III victory against an established immunotherapy standard in BTC. Could PD-1/VEGF bispecific antibodies replace conventional PD-L1 inhibition in first-line BTC? @OncoAlert @myESMO #ESMO26 #BiliaryTractCancer #Oncology